Myovant and Pfizer showed that deal-making was not taking a Christmas break, but for Celgene CVR holders the dream is almost over. And vaccine approvals gained pace.
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
December promises big US decisions for Novartis, Astrazeneca and Fibrogen, as well as the FDA's first Covid-19 vaccine reviews.
With one portfolio asset rejected by the FDA and another looking dicey, Sumitomo looks pretty reliant on Vibegron.
Few signs of a tightening regulatory climate can be found in approval numbers for 2020 – but some big decisions are still pending.
A crucial second pivotal trial in uterine fibroids fails to dispel concerns about the company’s linzagolix.